Alterations in functional networks contribute to depression in Parkinson’s disease: A resting-state functional magnetic resonance imaging study
Objective: The aim of this research was to investigate alterations in functional brain networks in PD patients with depression (DPD) and their association with demographic…Loss of cortical inhibition in Parkinson’s disease
Objective: To evaluate motor cortex inhibition at different stages of Parkinson’s disease (PD). Background: In PD, striatal dopamine depletion produces profound alterations in the neural…Pain syndrome in Parkinson’s disease: neurophysiological and MRI morphometric features
Objective: Investigation of the neurophysiological disorders and identify their structural correlates in the brain by MRI studies with using voxel-based morphometry to reveal subtle changes…Does constipation predict cognitive impairment and dementia in de novo Parkinson’s disease patients? A multi-cohort longitudinal data analysis
Objective: To investigate if constipation predicts the development of cognitive impairment (CI) and dementia in de novo Parkinson’s disease (PD). Background: Constipation is one of…Effects of Sleep Disorders on the Quality of Life in Parkinson’s Disease: A Study of 84 Ibadan Patients
Objective: To assess the effects of sleep disorders on the quality of life in PD patients. Background: Parkinson’s disease is a progressive neurodegenerative disease. The…Urinary Symptoms and Parkinson’s Disease: The Patient’s Perspective
Objective: To learn about prevalence rates and the impact of urinary symptoms on day-to-day function and quality of life from the patient’s perspective. Background: Urinary…Dietary and Plasma Polyunsaturated Fatty Acids in Parkinson’s Disease
Objective: We assessed the dietary intakes and plasma levels of polyunsaturated fatty acid (PUFA) in Parkinson's disease (PD), and their relation to motor and non-motor…Donepezil for mild cognitive impairment in Parkinson’s disease: A 48-week follow-up study
Objective: To investigate the efficacy of donepezil for mild cognitive impairment (MCI) in Parkinson’s disease (PD). Background: MCI is common in PD. The mechanism of…Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson’s Disease Patients with and without LRRK2 mutations
Objective: To evaluate safety, tolerability, and target engagement of DNL201, a LRRK2 inhibitor, in Parkinson’s disease (PD) patients. Background: Mutations in LRRK2 impact both familial…Rapid on-time onset and sustained improvements in motor states throughout the day following treatment with levodopa/carbidopa intestinal gel (LCIG) vs immediate-release levodopa/carbidopa oral capsules (LCIR)
Objective: To assess the speed of on-time onset and characterize the patterns of motor states throughout the day in advanced Parkinson’s disease patients treated with…
- « Previous Page
- 1
- …
- 96
- 97
- 98
- 99
- 100
- …
- 388
- Next Page »